JNJ

169.04

+0.68%↑

NVS

118.03

+0.91%↑

ABT

125.79

-0.06%↓

MDT

92.08

+0.27%↑

ELV.US

296.46

+5.26%↑

JNJ

169.04

+0.68%↑

NVS

118.03

+0.91%↑

ABT

125.79

-0.06%↓

MDT

92.08

+0.27%↑

ELV.US

296.46

+5.26%↑

JNJ

169.04

+0.68%↑

NVS

118.03

+0.91%↑

ABT

125.79

-0.06%↓

MDT

92.08

+0.27%↑

ELV.US

296.46

+5.26%↑

JNJ

169.04

+0.68%↑

NVS

118.03

+0.91%↑

ABT

125.79

-0.06%↓

MDT

92.08

+0.27%↑

ELV.US

296.46

+5.26%↑

JNJ

169.04

+0.68%↑

NVS

118.03

+0.91%↑

ABT

125.79

-0.06%↓

MDT

92.08

+0.27%↑

ELV.US

296.46

+5.26%↑

Search

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

305.27 -2.56

Overview

Share price change

24h

Current

Min

305.27

Max

321.81

Key metrics

By Trading Economics

Income

-14M

-73M

Sales

34M

137M

Profit margin

-53.361

Employees

528

EBITDA

-14M

-70M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+30.04% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

33M

7.3B

Previous open

307.83

Previous close

305.27

News Sentiment

By Acuity

50%

50%

114 / 375 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 lip 2025, 23:41 UTC

Earnings

SK Hynix Earnings Streak Continues on AI Chip Demand -- Update

23 lip 2025, 23:25 UTC

Earnings

Macquarie Group 1Q Profit Falls on Asset Management, Commodities Income

23 lip 2025, 23:10 UTC

Earnings

SK Hynix Earnings Streak Continues on AI Chip Demand

23 lip 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Enthusiasm Over U.S.-Japan Trade Deal -- Market Talk

23 lip 2025, 23:40 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

23 lip 2025, 23:37 UTC

Earnings

Macquarie Group 1Q Profit Falls on Asset Management, Commodities -- Update

23 lip 2025, 23:03 UTC

Earnings

Tesla Profit Falls, Hurt by Plunging EV Sales -- 7th Update

23 lip 2025, 22:47 UTC

Earnings

SK Hynix 2Q Net Profit Missed FactSet-Compiled Consensus

23 lip 2025, 22:45 UTC

Earnings

SK Hynix 2Q Net KRW6.996T Vs. Net KRW4.120T >000660.SE

23 lip 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Franco-Nevada: Announces Acquisition of 1.0% Net Smelter Return on AngloGold's Arthur Gold Project in Nevada

23 lip 2025, 22:44 UTC

Earnings

SK Hynix 2Q Oper Pft KRW9.213T Vs. Pft KRW5.469T >000660.SE

23 lip 2025, 22:43 UTC

Earnings

SK Hynix 2Q Rev KRW22.232T Vs. KRW16.423T >000660.SE

23 lip 2025, 22:38 UTC

Acquisitions, Mergers, Takeovers

Franco-Nevada Announces Acquisition of 1% NSR on AngloGold's Arthur Gold Project in Nevada

23 lip 2025, 22:30 UTC

Market Talk

Healthcare Providers Feel Pressure of Accelerating Medical Costs -- Market Talk

23 lip 2025, 22:20 UTC

Earnings

Northern Star Resources FY25 Cash Earnings A$2.8 Billion-A$2.95 Billion

23 lip 2025, 22:19 UTC

Earnings

Tesla Profit Falls, Hurt by Plunging EV Sales -- 6th Update

23 lip 2025, 22:18 UTC

Earnings

Northern Star Resources FY25 Group Underlying Free Cash Flow A$536 Million

23 lip 2025, 22:16 UTC

Earnings

Northern Star Resources 4Q All-in Sustaining Cost A$2,197/Oz

23 lip 2025, 22:16 UTC

Earnings

Northern Star Resources 4Q Gold Sales 444,034 Oz

23 lip 2025, 22:15 UTC

Earnings

Northern Star Resources FY25 Gold Sales 1.634 Million Oz

23 lip 2025, 21:59 UTC

Earnings

Tesla Profit Falls, Hurt by Plunging EV Sales -- 5th Update

23 lip 2025, 21:52 UTC

Earnings

T-Mobile Adds More Subscribers Than Rivals -- WSJ

23 lip 2025, 21:39 UTC

Earnings

There's Still No Growth at Railroader CSX -- Unless Buffett Makes a Bid -- Barrons.com

23 lip 2025, 21:25 UTC

Earnings

Google Earnings Roundly Beat Estimates. Growing CapEx Remains an Issue. -- Barrons.com

23 lip 2025, 21:19 UTC

Earnings

Chipotle Stock Falls After Earnings. Comparable Store Sales Are the Worry. -- Barrons.com

23 lip 2025, 21:13 UTC

Earnings

General Dynamics Beats Wall Street Estimates. The Stock Is Up. -- Barrons.com

23 lip 2025, 21:12 UTC

Earnings

Tesla Profit Falls, Hurt by Plunging EV Sales -- 4th Update

23 lip 2025, 21:04 UTC

Earnings

GE Vernova Stock Soared on Earnings Beat. Wall Street Loves the Power Firm. -- Barrons.com

23 lip 2025, 20:53 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

23 lip 2025, 20:53 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Energy Roundup: Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

30.04% upside

12 Months Forecast

Average 430.36 USD  30.04%

High 540 USD

Low 248 USD

Based on 13 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

114 / 375 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.